Results 131 to 140 of about 231,974 (295)

Para-aortic node involvement is not an independent predictor of survival after resection for pancreatic cancer [PDF]

, 2017
AIM To analyze the importance of para-aortic node status in a series of patients who underwent pancreaticoduodenectomy (PD) in a single Institution.
Beltrame, Valentina, Blandamura, Stella, Gruppo, Mario, Moletta, Lucia, Passuello, Nicola, Pozza, Gioia, Sperti, Cosimo, Valmasoni, Michele   +7 more
core   +1 more source

Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix.

Journal of Clinical Investigation, 2020
Desmoplasia describes the deposition of extensive extracellular matrix and defines primary pancreatic ductal adenocarcinoma (PDA). The acellular component of this stroma has been implicated in PDA pathogenesis and is being targeted therapeutically in ...
Honglin Jiang, R. Torphy, K. Steiger, H. Hongo, A. Ritchie, M. Kriegsmann, D. Horst, S. Umetsu, N. Joseph, K. McGregor, M. Pishvaian, E. Blais, B. Lu, Mingyu Li, M. Hollingsworth, C. Stashko, Keith E. Volmar, J. Yeh, V. Weaver, Zhen J. Wang, M. Tempero, W. Weichert, E. Collisson   +22 more
semanticscholar   +1 more source

Imaging for pancreatic ductal adenocarcinoma

Chinese Clinical Oncology, 2017
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers worldwide due to its aggressiveness and the challenge to early diagnosis. Complete surgical resection is the only curative option, but fewer than 20% of patients have potentially resectable disease at the time of the diagnosis.
Natally, Horvat, Davinia E, Ryan, Maria D, LaGratta, Pari M, Shah, Richard Kinh, Do   +4 more
openaire   +2 more sources

The predictors and patterns of the early recurrence of pancreatic ductal adenocarcinoma after pancreatectomy: the influence of pre- and post- operative adjuvant therapy

BMC Surgery, 2019
Background The perioperative factors predicting or influencing early pancreatic ductal adenocarcinoma recurrence are unclear. This study attempted to identify the predictive factors for early pancreatic ductal adenocarcinoma recurrence post ...
Hironobu Suto, Keiichi Okano, Minoru Oshima, Yasuhisa Ando, Shigeo Takahashi, Toru Shibata, Hideki Kamada, Hideki Kobara, Tsutomu Masaki, Yasuyuki Suzuki   +9 more
doaj   +1 more source

A33 shows similar sensitivity to but is more specific than CDX2 as an immunomarker of colorectal carcinoma [PDF]

, 2017
Aims: CDX2 is widely used as a sensitive and specific immunomarker for colorectal carcinoma (CRC) but neither this sensitivity nor specificity is absolute. This study is the first known comparison of CDX1 and A33 against CDX2 as immunomarkers for CRC.
Adamczyk, Lukasz A., Cullen, Jayne, Evans, Shanna, Oien, Karin A., Oniscu, Anca, Wong, Newton A.C.S.   +5 more
core   +1 more source

Cellular Membrane Localization of Innate Immune Checkpoint Molecule CD47 Is Regulated by Radixin in Human Pancreatic Ductal Adenocarcinoma Cells [PDF]

, 2023
Takuro Kobori, Yui Ito, Yuka Sawada, Yoko Urashima, Takuya Ito, Tokio Obata   +5 more
openalex   +1 more source

SLC39A1 contributes to gemcitabine resistance of pancreatic ductal adenocarcinoma by activating AMPK signaling

Bangladesh Journal of Pharmacology
Gemcitabine is a common first-line chemotherapy agent, but gemcitabine resistance is a clinical challenge for pancreatic ductal adenocarcinoma patients.
Hao Yu, Xiaoping Mei, Xueming Zhang, Neng Qian, Qingjiang Yu, Hongkun Zhou   +5 more
doaj   +1 more source

Crosstalk between Tumor and Stromal Cells in Pancreatic Ductal Adenocarcinoma

International Journal of Molecular Sciences, 2020
Pancreatic ductal adenocarcinoma (PDAC) remains a lethal cancer. The poor prognosis calls for a more detailed understanding of disease biology in order to pave the way for the development of effective therapies.
Nadine Sperb, M. Tsesmelis, T. Wirth
semanticscholar   +1 more source

MicroRNAs in pancreatic ductal adenocarcinoma

World Journal of Gastroenterology, 2011
Ductal adenocarcinoma of the pancreas is a lethal cancer for which the only chance of long-term survival belongs to the patient with localized disease in whom a potentially curative resection can be done. Therefore, biomarkers for early detection and new therapeutic strategies are urgently needed.
Jong Y, Park, James, Helm, Domenico, Coppola, Donghwa, Kim, Mokenge, Malafa, Seung Joon, Kim   +5 more
openaire   +2 more sources

The Potential for Circulating Tumor Cells in Pancreatic Cancer Management. [PDF]

, 2017
Pancreatic cancer is one the most lethal malignancies. Only a small proportion of patients with this disease benefit from surgery. Chemotherapy provides only a transient benefit.
Michael Pimienta, Michael Pimienta, Mouad Edderkaoui, Ruoxiang Wang, Stephen Pandol   +4 more
core   +2 more sources